IP Group's investments are paying off

IP Group PLC (LSE:IPO) anticipates significant future royalty income from obesity drug programs, stemming from its licensed technology following Pfizer's acquisition of Metsera, with potential sales by 2029-2030, which could become a substantial long-term revenue stream. The company also reported strong portfolio realisations, achieving £160 million in 2024 and projecting over £250 million from 2025-2027, signaling a maturing asset base and favorable exit environment. Concurrently, IP Group invested £4 million in clean tech firm OXCCU as part of a $28 million funding round, attracting strategic investors like IAG for its sustainable aviation fuel technology.

Analysis

IP Group (LSE:IPO) is poised for substantial future royalty income from its foundational technology licensed to Metsera, following Pfizer's (PFE) acquisition of Metsera for up to $7.3 billion, including a nearly $5 billion upfront payment. Metsera's lead anti-obesity compounds, based on IP Group's 1996 GLP-1 discovery, are targeting Phase 3 trials by year-end, with first sales projected for 2029-2030, potentially transforming IP Group's growth model towards long-term revenue streams. This opportunity, previously overlooked by the market, represents a significant source of future value.

The company demonstrated robust portfolio maturation, achieving £160 million in realisations in 2024, successfully navigating a challenging venture market. Key exits included Monolith to CoreWeave, Featurespace to Visa, and Garrison Technology to Everfox. IP Group projects over £250 million in further realisations from its private portfolio between 2025 and 2027, underscoring an attractive M&A environment for its high-quality assets.

Strategically, IP Group invested £4 million into OXCCU, a clean tech innovator, as part of a $28 million funding round that attracted notable third-party investors like International Airlines Group (IAG) and Safran Corporate Ventures. OXCCU's focus on Sustainable Aviation Fuel (SAF) aligns with strong regulatory and industry drivers, such as IAG's commitment to 10% SAF by 2030, highlighting IP Group's commitment to high-impact, high-return opportunities and effective capital recycling.

Key Decisions for Investors

• Investors should closely monitor Metsera's clinical trial progress and regulatory approvals for the anti-obesity drugs, as successful commercialization by 2029-2030 could significantly boost IP Group's long-term revenue profile.
• Assess IP Group's ability to meet its projected £250 million-plus realisation target for 2025-2027, as continued successful exits validate portfolio quality and provide capital for reinvestment or shareholder returns.
• Evaluate IP Group's increasing exposure to the clean tech sector, particularly through OXCCU's SAF technology, given the strong industry tailwinds and strategic investor backing, which could offer future growth potential.